Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC

Published:2014-11-25 Issue: Volume:4 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Zer Alona,Leighl Natasha

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference64 articles.

1. Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second- and third-line;Leighl;Curr Oncol,2012

2. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

3. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

4. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology;Lindeman;J Thorac Oncol,2013

5. Screening for epidermal growth factor receptor mutations in lung cancer;Rosell;N Engl J Med,2009

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomic Features of Organ-Specific Metastases in Lung Adenocarcinoma;Frontiers in Oncology;2022-07-14

2. Survival Outcomes and Predictors for Recurrence of Surgically Treated Brain Metastasis From Non-Small Cell Lung Cancer;Brain Tumor Research and Treatment;2022

3. Evaluation of Oxidative Stress Biomarkers in Brain Metastatic and Non-Metastatic Lung Cancer Patients with Different Cell Types;Anti-Cancer Agents in Medicinal Chemistry;2021-09-08

4. Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report;Clinical Drug Investigation;2021-04-16

5. Association between epidermal growth factor receptor mutation status, clinicopathological characteristics and TTF-1 expression in lung adenocarcinoma: A single center study;Srpski arhiv za celokupno lekarstvo;2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3